Added to YB: 2026-09-08
Pitch date: 2026-09-05
EBS [neutral]
Emergent BioSolutions Inc.
Author Info
I research and share thesis-driven ideas on potential healthcare multibaggers. Sign up for the newsletter.
Company Info
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally.
Market Cap
$318.4M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
3.30
P/E
-1.83
EV/Sales
1.00
Sector
Biotechnology
Category
N/A
This Week in Healthcare - Issue #1 - Emergent BioSolutions Inc.
EBS (update): Emergent BioSolutions received a Canadian NARCAN standing offer permitting designated public-sector purchases from October 2026 through September 2029, with a two-year extension option, and a roughly $24 million BARDA contract modification for CYFENDUS. It also repurchased $75 million of 2028 notes for approximately $68 million, leaving approximately $364.7 million outstanding; the NARCAN offer’s value and CYFENDUS delivery timing were not disclosed.
Read full article (1 min)